RT Journal Article
SR Electronic
T1 SGLT2 inhibition reduces cardiac surgery-associated acute kidney injury: An open-label randomized study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.27.24304998
DO 10.1101/2024.03.27.24304998
A1 Snel, Lars I.P.
A1 Oosterom-Eijmael, Maartina J.P.
A1 Rampanelli, Elena
A1 Lankadeva, Yugeesh R.
A1 Plummer, Mark P.
A1 Preckel, Benedikt
A1 Hermanides, Jeroen
A1 van Raalte, Daniel H.
A1 Hulst, Abraham H.
YR 2024
UL http://medrxiv.org/content/early/2024/03/28/2024.03.27.24304998.abstract
AB Background Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common postoperative complication. Currently, no effective preventative strategies exist to mitigate CSA-AKI. Sodium-glucose transporter-2 (SGLT2) inhibitors reduced acute kidney injury (AKI) incidence in large, randomized placebo-controlled, cardiovascular and kidney outcome trials conducted in patients with chronic kidney disease. We hypothesized that perioperative SGLT2 inhibition could also reduce CSA-AKI.Methods In this open-label phase IV, randomized, parallel-group, pilot study, adult patients undergoing elective cardiac surgery with cardiopulmonary bypass were randomized to receive the SGLT2 inhibitor, empagliflozin (10 mg; oral), once daily three days prior to surgery and continued to two days after surgery compared with standard-of-care. Biomarkers for acute kidney injury (AKI), including serum and urinary neutrophil gelatinase-associated lipocalin (NGAL), serum and urinary kidney injury molecule-1 (KIM-1), and serum hypoxia-inducible factor-1α (HIF-1α) were measured. Additional outcomes included AKI incidence according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria as well as metabolic parameters, including ketone body concentrations and glycemic control.Results Between March 2022 and April 2023, 55 patients were included (sex: 73% male, age: 66 ± 10 years, BMI: 28 ± 4 kg/m2, empagliflozin n = 25, control n = 30) in the intention-to-treat analysis. Empagliflozin significantly reduced the incidence of AKI (20% vs 66.7%; absolute difference 46.7%, 95% CI, –69.7 – –23.6; P=.001). Following surgery, urinary NGAL, and KIM-1 were found to increase in both arms, whereas a significant increment in serum HIF-1α after surgery was solely observed in the control group. We observed no between-group differences in the incidence of (euglycemic) ketoacidosis or hypoglycemic events.Conclusions Perioperative SGLT2 inhibition, compared with standard of care, significantly reduced the incidence of CSA-AKI. These findings warrant validation in large-scale, double-blind, placebo-controlled, randomized trials.Trial Registry https://onderzoekmetmensen.nl/en/trial/26563 Identifier: NL9561In this open-label, randomized, controlled, pilot trial perioperative use of sodium glucose transporter-2 (SGLT2) inhibition with empagliflozin significantly reduced the incidence of acute kidney injury (AKI) by 46.7% (95% CI, –69.7 – –23.6; P=.001) compared to the control group.The level of ketone bodies increased significantly during cardiac surgery, however, there was no additional effect of empagliflozin treatment.These results suggest that perioperative treatment with SGLT2 inhibitors might decrease the risk of cardiac surgery-associated (CSA)-AKI.These findings warrant validation in large-scale, double-blind, placebo-controlled, randomized trial, which is currently ongoing.Competing Interest StatementDHR has served as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Novo Nordisk,Sanofi, and AstraZeneca and has received research operating funds from Boehringer Ingelheim and Lilly Diabetes Alliance, AstraZeneca, and NovoNordisk; all honoraria are paid to his employer (Amsterdam University Medical Center, Amsterdam). All other authors declare no conflict of interests.Clinical Trialhttps://onderzoekmetmensen.nl/en/trial/26563 Identifier: NL9561Funding Statement?This project has received funding from the European Union?s Horizon 2020 research and innovation program under the Marie Sk?odowska-Curie grant agreement No 101024833.?Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:MERC Amsterdam UMCI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData available upon reasonable request.AKIAcute kidney injuryCIConfidence intervalCKDChronic kidney diseaseCPBCardiopulmonary bypassCSA-AKICardiac surgery-associated acute kidney injuryeGFRestimated glomerular filtration rateHIF1αHypoxia-inducible factor 1 alphaIUInternational unitsKIM-1Kidney injury molecule 1NGALNeutrophil gelatinase-associated lipocalinKDIGOKidney Disease: Improving Global OutcomesSGLT2Sodium-glucose transporter-2T1DType 1 diabetesT2DType 2 diabetes